Device Trial Radar · NCT06517576
Using Remote Monitoring to Address Health Disparities in Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 1, 2024
Primary completion
Dec 31, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Lawndale Christian Health CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Chicago
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patient populations at community health centers, specifically Black or African American and Hispanic or Latino populations with Type 2 diabetes, experience significant health disparities. In particular, they have higher rates of diabetes-related complications and other related conditions such as myocardial infarction, cerebrovascular disease, kidney failure, blindness, neuropathy, and the risk of amputation. Diabetes affects 34 million adults in the US. Achieving a target HbA1c less than 8% can be challenging through diabetes management. Patients are able to monitor their blood glucose levels with devices such as blood glucose meters or continuous glucose monitors to facilitate diabetes management and glycemic control. Past studies have demonstrated that these devices are effective in engaging patients in the improvement of diabetes management. Current advancements in remote patient monitoring and self-monitoring have been observed to be effective in facilitating improvement in diabetes outcomes. However, the effectiveness and financial feasibility of these devices delivered in conjunction with automated patient engagement systems in remote patient monitoring programs is not well understood among underinsured, underserved, and vulnerable minority populations as they face a high-cost barrier particularly with continuous glucose monitors. To better address this gap in knowledge, this pilot study will compare and examine the effectiveness of these interventions on patient outcomes with Type 2 diabetes among populations in the West Side of Chicago. Study the comparative effectiveness among patients with uncontrolled Type 2 diabetes on insulin in an intervention group using remote patient monitoring and automated patient engagement system with blood glucose monitors to a group using a self-monitoring program with continuous glucose monitors and a usual care group receiving standard care. Conduct a feasibility analysis and financial impact of these programs among an underinsured and underserved population of Black/African Americans or Hispanic/Latinos with Type 2 diabetes.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Blood glucose monitor with Digital Platform and Health CoachingDevice
Blood glucose monitors will be used daily to measure blood glucose measurements.
Continuous glucose monitorDevice
Continuous glucose monitors will be used daily to measure blood glucose measurements.
Usual CareOther
Usual care for type 2 diabetes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glycated HemoglobinTime frame: Baseline and at 4 Months
- Blood GlucoseTime frame: 4 Months
- Engagement with digital platform with a daily submission of blood glucoseTime frame: 4 Months
4 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lawndale Christian Health Center
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.